Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 3,074 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $76,850.00. Following the completion of the sale, the insider now owns 127,634 shares of the company’s stock, valued at approximately $3,190,850. This represents a 2.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Peter Heerma also recently made the following trade(s):

• On Wednesday, January 22nd, Peter Heerma sold 1,584 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total value of $30,000.96.

Travere Therapeutics Stock Performance

Travere Therapeutics stock opened at $23.20 on Thursday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $25.29. The company has a fifty day simple moving average of $19.06 and a 200 day simple moving average of $15.95.

Hedge Funds Weigh In On Travere Therapeutics

A number of large investors have recently modified their holdings of TVTX. Aigen Investment Management LP acquired a new stake in shares of Travere Therapeutics in the third quarter valued at about $170,000. Oppenheimer & Co. Inc. bought a new position in Travere Therapeutics in the third quarter valued at approximately $673,000. FMR LLC increased its position in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock worth $2,062,000 after purchasing an additional 31,772 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Travere Therapeutics by 30.2% during the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock worth $10,078,000 after purchasing an additional 167,100 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after buying an additional 64,744 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on TVTX shares. Piper Sandler raised their price target on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Scotiabank increased their target price on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. Canaccord Genuity Group lifted their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald initiated coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating for the company. Finally, Barclays raised their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.